Research ExplorerPublicationsLiquid biopsy-based clinical research in early breast cancer...

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial

Standard

Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. / Ignatiadis, Michail; Rack, Brigitte; Rothé, Francoise; Riethdorf, Sabine; Decraene, Charles; Bonnefoi, Hervé; Dittrich, Christian; Messina, Carlo; Beauvois, Melanie; Trapp, Elisabeth; Goulioti, Theodora; Tryfonidis, Konstantinos; Pantel, Klaus; Repollet, Madeline; Janni, Wolfgang; Piccart, Martine; Sotiriou, Christos; Litiere, Saskia; Pierga, Jean-Yves.

In: EUR J CANCER, Vol. 63, 08.2016, p. 97-104.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ignatiadis, M, Rack, B, Rothé, F, Riethdorf, S, Decraene, C, Bonnefoi, H, Dittrich, C, Messina, C, Beauvois, M, Trapp, E, Goulioti, T, Tryfonidis, K, Pantel, K, Repollet, M, Janni, W, Piccart, M, Sotiriou, C, Litiere, S & Pierga, J-Y 2016, 'Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial', EUR J CANCER, vol. 63, pp. 97-104. https://doi.org/10.1016/j.ejca.2016.04.024

APA

Ignatiadis, M., Rack, B., Rothé, F., Riethdorf, S., Decraene, C., Bonnefoi, H., Dittrich, C., Messina, C., Beauvois, M., Trapp, E., Goulioti, T., Tryfonidis, K., Pantel, K., Repollet, M., Janni, W., Piccart, M., Sotiriou, C., Litiere, S., & Pierga, J-Y. (2016). Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. EUR J CANCER, 63, 97-104. https://doi.org/10.1016/j.ejca.2016.04.024

Vancouver

Ignatiadis M, Rack B, Rothé F, Riethdorf S, Decraene C, Bonnefoi H et al. Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial. EUR J CANCER. 2016 Aug;63:97-104. https://doi.org/10.1016/j.ejca.2016.04.024

Bibtex

@article{6027f228dcda419e8b17037f189ca4ba,
title = "Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial",
abstract = "There is increasing evidence that breast cancer evolves over time under the selection pressure of systemic treatment. Today, treatment decisions in early breast cancer are based on primary tumour characteristics without considering the disease evolution. Chemoresistant micrometastatic disease is poorly characterised and thus it is not used in current clinical practice as a tool to personalise treatment approaches. The detection of chemoresistant circulating tumour cells (CTCs) has been shown to be associated with worse prognosis in early breast cancer. The ongoing Treat CTC trial is the first international, liquid biopsy-based trial evaluating the concept of targeting chemoresistant minimal residual disease: detection of CTCs following adjuvant chemotherapy (adjuvant cohort) or neoadjuvant chemotherapy in patients who did not achieve pathological complete response (neoadjuvant cohort). This article presents the rational and design of this trial and the results of the pilot phase after 350 patients have been screened and provides insights that might provide information for future trials using the liquid biopsy approach as a tool towards precision medicine (NCT01548677).",
keywords = "Journal Article, Review",
author = "Michail Ignatiadis and Brigitte Rack and Francoise Roth{\'e} and Sabine Riethdorf and Charles Decraene and Herv{\'e} Bonnefoi and Christian Dittrich and Carlo Messina and Melanie Beauvois and Elisabeth Trapp and Theodora Goulioti and Konstantinos Tryfonidis and Klaus Pantel and Madeline Repollet and Wolfgang Janni and Martine Piccart and Christos Sotiriou and Saskia Litiere and Jean-Yves Pierga",
note = "Copyright {\textcopyright} 2016 Elsevier Ltd. All rights reserved.",
year = "2016",
month = aug,
doi = "10.1016/j.ejca.2016.04.024",
language = "English",
volume = "63",
pages = "97--104",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Liquid biopsy-based clinical research in early breast cancer: The EORTC 90091-10093 Treat CTC trial

AU - Ignatiadis, Michail

AU - Rack, Brigitte

AU - Rothé, Francoise

AU - Riethdorf, Sabine

AU - Decraene, Charles

AU - Bonnefoi, Hervé

AU - Dittrich, Christian

AU - Messina, Carlo

AU - Beauvois, Melanie

AU - Trapp, Elisabeth

AU - Goulioti, Theodora

AU - Tryfonidis, Konstantinos

AU - Pantel, Klaus

AU - Repollet, Madeline

AU - Janni, Wolfgang

AU - Piccart, Martine

AU - Sotiriou, Christos

AU - Litiere, Saskia

AU - Pierga, Jean-Yves

N1 - Copyright © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/8

Y1 - 2016/8

N2 - There is increasing evidence that breast cancer evolves over time under the selection pressure of systemic treatment. Today, treatment decisions in early breast cancer are based on primary tumour characteristics without considering the disease evolution. Chemoresistant micrometastatic disease is poorly characterised and thus it is not used in current clinical practice as a tool to personalise treatment approaches. The detection of chemoresistant circulating tumour cells (CTCs) has been shown to be associated with worse prognosis in early breast cancer. The ongoing Treat CTC trial is the first international, liquid biopsy-based trial evaluating the concept of targeting chemoresistant minimal residual disease: detection of CTCs following adjuvant chemotherapy (adjuvant cohort) or neoadjuvant chemotherapy in patients who did not achieve pathological complete response (neoadjuvant cohort). This article presents the rational and design of this trial and the results of the pilot phase after 350 patients have been screened and provides insights that might provide information for future trials using the liquid biopsy approach as a tool towards precision medicine (NCT01548677).

AB - There is increasing evidence that breast cancer evolves over time under the selection pressure of systemic treatment. Today, treatment decisions in early breast cancer are based on primary tumour characteristics without considering the disease evolution. Chemoresistant micrometastatic disease is poorly characterised and thus it is not used in current clinical practice as a tool to personalise treatment approaches. The detection of chemoresistant circulating tumour cells (CTCs) has been shown to be associated with worse prognosis in early breast cancer. The ongoing Treat CTC trial is the first international, liquid biopsy-based trial evaluating the concept of targeting chemoresistant minimal residual disease: detection of CTCs following adjuvant chemotherapy (adjuvant cohort) or neoadjuvant chemotherapy in patients who did not achieve pathological complete response (neoadjuvant cohort). This article presents the rational and design of this trial and the results of the pilot phase after 350 patients have been screened and provides insights that might provide information for future trials using the liquid biopsy approach as a tool towards precision medicine (NCT01548677).

KW - Journal Article

KW - Review

U2 - 10.1016/j.ejca.2016.04.024

DO - 10.1016/j.ejca.2016.04.024

M3 - SCORING: Journal article

C2 - 27289552

VL - 63

SP - 97

EP - 104

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -